Carbon Monoxide as Experimental Medicine: Inhaled CO and CORMs

Because low-dose carbon monoxide is anti-inflammatory, anti-apoptotic and cytoprotective — acting through the heme oxygenase → CO → soluble guanylate cyclase pathway — there is a serious effort to administer it deliberately as a drug. The premise sounds absurd and follows directly from the biology: the body already manufactures CO on purpose as a signalling molecule. See Gasotransmitters: The Lethal Gases Your Body Manufactures as Signals. ## Inhaled low-dose CO A Phase I trial evaluated inhaled CO in **sepsis-induced ARDS**, at 100–200 ppm for 90 minutes daily for up to five days. The results were encouraging in the limited sense a Phase I result can be: it was safe, carboxyhaemoglobin stayed below 10%, and circulating markers of mitochondrial DNA damage were reduced. A follow-up study personalises the dose using the **Coburn–Forster–Kane equation** — the standard model of CO uptake — to target a specific COHb of around 6–8% in each patient rather than delivering a fixed concentration. Personalising to a blood level rather than an inhaled concentration is the right approach for a drug whose therapeutic window is defined by exactly that number. ## CO-releasing molecules **CORMs** are the drug-delivery answer to the obvious objection that asking a critically ill patient to inhale a poison is awkward. They are transition-metal carbonyl compounds — ruthenium-based CORM-2 and CORM-3, manganese-based CORM-401, and light-triggered photoCORMs — that carry CO and release it in target tissue. The advantages are localised delivery and avoidance of systemic inhalation. The problem is the carrier: the metal complex has its own toxicity and its own fate in the body, and separating the effects of released CO from effects of the carrier has been a persistent difficulty in interpreting CORM studies. ## The honest assessment The biology is real and the Phase I safety data are encouraging. Nothing is approved, and there are two hard problems. **The therapeutic window.** It is still CO, and it still binds haemoglobin ~200 times more avidly than oxygen. The margin between a signalling dose and a toxic one is narrow and depends on patient factors — cardiac disease, anaemia, pregnancy — that shift it further. **Carrier toxicity** for the CORM route, which is a chemistry problem rather than a biology one and may be soluble with better carriers. ## The framing This is the sharpest available illustration that the dose makes the poison. The same molecule that kills families in their sleep is, at a whisper of the dose, an anti-inflammatory drug candidate — and is manufactured continuously inside every person reading this. CO joins nitric oxide, whose pharmacology built an industry, and hydrogen sulphide as the third gasotransmitter: three lethal gases that the body makes on purpose as internal messages. See Carbon Monoxide Poisoning: Why You Cannot Build Useful Tolerance for the other end of the same molecule's range.